Literature DB >> 11448028

Attenuation of a field Sendai virus isolate through egg-passages is associated with an impediment of viral genome replication in mouse respiratory cells.

K Kiyotani1, T Sakaguchi, Y Fujii, T Yoshida.   

Abstract

We investigated the mechanisms responsible for attenuation of mouse pathogenicity of Sendai virus (SeV) through passages in eggs. A highly virulent clone, E0, derived from the field SeV Hamamatsu strain, was successively passaged in hen's eggs. Analysis of the mouse lethal dose 50% (MLD50) of virus clones obtained from the viruses at egg-passages 1, 15, 30 and 50 demonstrated that attenuation of E0 by egg-passage occurred due to the gradual appearance of and replacement by virus variants possessing higher MLD50. Comparison of viral replication in the mouse lung and mouse pathogenicity with the representative SeV clones, E0, E15c12, E30c12 and E50c19, obtained from the respective egg-passages revealed that the low pathogenicity of the egg-passaged clones was due to poor multi-cycle viral replication in the lung. Furthermore, MLD50s of the SeV clones were found to be negatively correlated with the replication capability in primary mouse pulmonary epithelial (MPE) cells; the egg-passaged clones with more attenuated phenotypes showed lower replication capability in MPE cells. In the MPE cells infected with the SeV clones at m.o.i. 10, however, viral protein and mRNA syntheses of the egg-passaged clones were enhanced or comparable to those of the parental E0 clone at 1 day and 2 days post infection (p.i.) but decreased more rapidly thereafter. In contrast, viral genome synthesis of the egg-passaged clones in the cells at 2 days p.i. was several times lower than that of E0. These results strongly suggest that attenuation of a virulent field SeV strain by egg-passage occurs due to the appearance and selection of virus variants possessing poor propagation capacity in mouse respiratory epithelial cells, which is caused primarily by an impediment of viral genome replication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448028     DOI: 10.1007/s007050170123

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  6 in total

1.  Inhibition of interferon regulatory factor 3 activation by paramyxovirus V protein.

Authors:  Takashi Irie; Katsuhiro Kiyotani; Tomoki Igarashi; Asuka Yoshida; Takemasa Sakaguchi
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Identification of mutations associated with attenuation of virulence of a field Sendai virus isolate by egg passage.

Authors:  Yutaka Fujii; Takemasa Sakaguchi; Katsuhiro Kiyotani; Chen Huang; Noriko Fukuhara; Tetsuya Yoshida
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

3.  Involvement of the leader sequence in Sendai virus pathogenesis revealed by recovery of a pathogenic field isolate from cDNA.

Authors:  Yutaka Fujii; Takemasa Sakaguchi; Katsuhiro Kiyotani; Cheng Huang; Noriko Fukuhara; Yoshiko Egi; Tetsuya Yoshida
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

4.  Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy.

Authors:  Crystal W Burke; John N Mason; Sherri L Surman; Bart G Jones; Emilie Dalloneau; Julia L Hurwitz; Charles J Russell
Journal:  PLoS Pathog       Date:  2011-07-07       Impact factor: 6.823

5.  Sendai virus intra-host population dynamics and host immunocompetence influence viral virulence during in vivo passage.

Authors:  José Peña; Haiyin Chen-Harris; Jonathan E Allen; Mona Hwang; Maher Elsheikh; Shalini Mabery; Helle Bielefeldt-Ohmann; Adam T Zemla; Richard A Bowen; Monica K Borucki
Journal:  Virus Evol       Date:  2016-04-09

6.  Passage of a Sendai virus recombinant in embryonated chicken eggs leads to markedly rapid accumulation of U-to-C transitions in a limited region of the viral genome.

Authors:  Asuka Yoshida; Takemasa Sakaguchi; Takashi Irie
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.